Summit Therapeutics Inc.
SMMT
$18.91
-$1.55-7.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 60.53M | 57.67M | 42.71M | 35.05M | 30.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -313.00K | -287.00K | -816.00K | -630.00K | -1.00M |
| Total Operating Expenses | 210.99M | 181.59M | 143.70M | 114.89M | 88.74M |
| Operating Income | -210.99M | -181.59M | -143.70M | -114.89M | -88.74M |
| Income Before Tax | -221.32M | -196.68M | -161.69M | -116.03M | -614.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -221.32 | -196.68 | -161.69 | -116.03 | -614.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -221.32M | -196.68M | -161.69M | -116.03M | -614.93M |
| EBIT | -210.99M | -181.59M | -143.70M | -114.89M | -88.74M |
| EBITDA | -210.90M | -181.49M | -143.59M | -114.75M | -88.54M |
| EPS Basic | -0.31 | -0.28 | -0.23 | -0.17 | -1.54 |
| Normalized Basic EPS | -0.18 | -0.16 | -0.13 | -0.10 | -0.10 |
| EPS Diluted | -0.32 | -0.28 | -0.23 | -0.17 | -1.54 |
| Normalized Diluted EPS | -0.18 | -0.16 | -0.13 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 2.87B | 2.84B | 2.81B | 2.80B | 2.47B |
| Average Diluted Shares Outstanding | 2.87B | 2.84B | 2.81B | 2.80B | 2.47B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
